![](https://endpts.com/wp-content/uploads/2023/07/John-Oyler-BeiGene-BIIS18-tile.jpg)
John Oyler, BeiGene CEO (Endpoints News, PharmCube)
BeiGene ends pact with Shoreline, its 'entry into cell therapy'
BeiGene said its four-target natural killer cell therapy collaboration with Shoreline Biosciences is over. And by reneging on Shoreline’s iPSC-NK cell …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.